menu
    • menu
    [{"orgOrder":0,"company":"Sunesis Pharmaceuticals","sponsor":"Oppenheimer & Co. Inc.","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Public Offering","leadProduct":"SNS-510","moa":"PDK-1","graph1":"Oncology","graph2":"Preclinical","graph3":"Sunesis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sunesis Pharmaceuticals \/ Oppenheimer & Co. Inc.","highestDevelopmentStatusID":"4","companyTruncated":"Sunesis Pharmaceuticals \/ Oppenheimer & Co. Inc."},{"orgOrder":0,"company":"Sunesis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"SNS-510","moa":"PDK-1","graph1":"Oncology","graph2":"Preclinical","graph3":"Sunesis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sunesis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Sunesis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Sunesis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Vecabrutinib","moa":"BTK","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sunesis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Sunesis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Sunesis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Sunesis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"SNS-510","moa":"PDK-1","graph1":"Oncology","graph2":"Preclinical","graph3":"Sunesis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sunesis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Sunesis Pharmaceuticals \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Sunesis Pharmaceuticals

    Menu

    Sunesis Pharmaceuticals

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Sunesis Pharmaceuticals

                            U.S.A arrow
                            Peptide Therapy Summit
                            Not Confirmed

                            Sunesis Pharmaceuticals

                            U.S.A arrow
                            Peptide Therapy Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SNS-510

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Sunesis Announces Presentation of SNS-510 Preclinical Data at the 32nd EORTC-NCI-AACR Symposium on Molecular T...

                            Details : Abstract titled "PDK1 inhibitor SNS-510 shows synergy with standard cancer therapies in solid tumor and hematologic cancer models " will be presented at the conference.

                            Product Name : SNS-510

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            December 10, 2020

                            Lead Product(s) : SNS-510

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Sunesis Pharmaceuticals

                            U.S.A arrow
                            Peptide Therapy Summit
                            Not Confirmed

                            Sunesis Pharmaceuticals

                            U.S.A arrow
                            Peptide Therapy Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SNS-510

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Oppenheimer & Co. Inc.

                            Deal Size : $12.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Sunesis Announces Pricing of $12 Million Offering of Common Stock

                            Details : Sunesis anticipates using the net proceeds from the proposed offering to fund ongoing development of PDK1 inhibitor SNS-510 and general corporate purposes.

                            Product Name : SNS-510

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            July 28, 2020

                            Lead Product(s) : SNS-510

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Oppenheimer & Co. Inc.

                            Deal Size : $12.0 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Sunesis Pharmaceuticals

                            U.S.A arrow
                            Peptide Therapy Summit
                            Not Confirmed

                            Sunesis Pharmaceuticals

                            U.S.A arrow
                            Peptide Therapy Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SNS-510

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Sunesis Reduces Workforce to Focus on Development of PDK1 inhibitor, SNS-510

                            Details : The changes will extend Sunesis's cash runway and provide it with the necessary resources to execute on its PDK1 program evaluating its PDK1 inhibitor SNS-510, while also allowing the flexibility to explore opportunities for additional value creation.

                            Product Name : SNS-510

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            July 07, 2020

                            Lead Product(s) : SNS-510

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Sunesis Pharmaceuticals

                            U.S.A arrow
                            Peptide Therapy Summit
                            Not Confirmed

                            Sunesis Pharmaceuticals

                            U.S.A arrow
                            Peptide Therapy Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Vecabrutinib

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Sunesis Pharmaceuticals Announces Clinical Update on Vecabrutinib Program

                            Details : Company will not advance its non-covalent BTK inhibitor vecabrutinib into the planned Phase 2 portion of the Phase 1b/2 trial in adults with relapsed/refractory chronic lymphocytic leukemia and other B-cell malignancies.

                            Product Name : SNS-062

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            June 23, 2020

                            Lead Product(s) : Vecabrutinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth